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Abstract 25 
Anti-apoptotic B-cell lymphoma 2 (Bcl-2) family members target several intracellular Ca
2+
-26 
transport systems. Bcl-2, via its N-terminal Bcl-2 homology (BH) 4 domain, inhibits both 27 
inositol 1,4,5-trisphosphate receptors (IP3Rs) and ryanodine receptors (RyRs), while Bcl-XL, 28 
likely independently of its BH4 domain, sensitizes IP3Rs. It remains elusive whether Bcl-XL 29 
can also target and modulate RyRs. Here, Bcl-XL co-immunoprecipitated with RyR3 30 
expressed in HEK293 cells. Mammalian protein-protein interaction trap (MAPPIT) and 31 
surface plasmon resonance (SPR) showed that Bcl-XL bound to the central domain of RyR3 32 
via its BH4 domain, although to a lesser extent compared to the BH4 domain of Bcl-2. 33 
Consistent with the ability of the BH4 domain of Bcl-XL to bind to RyRs, loading the BH4-34 
Bcl-XL peptide into RyR3-overexpressing HEK293 cells or in rat hippocampal neurons 35 
suppressed RyR-mediated Ca
2+
 release. In silico superposition of the 3D-structures of Bcl-2 36 
and Bcl-XL indicated that Lys87 of the BH3 domain of Bcl-XL could be important for 37 
interacting with RyRs. In contrast to Bcl-XL, the Bcl-XL
K87D
 mutant displayed lower binding 38 
affinity for RyR3 and a reduced inhibition of RyR-mediated Ca
2+
 release. These data suggest 39 
that Bcl-XL binds to RyR channels via its BH4 domain, but also its BH3 domain, more 40 
specific Lys87, contributes to the interaction. 41 
42 
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Introduction 43 
The B-cell lymphoma 2 (Bcl-2) protein family has long been studied with respect to its 44 
prominent role in the regulation of apoptosis 
1,2
. Beyond this, it is becoming increasingly clear 45 
that both the pro- and anti-apoptotic Bcl-2 family proteins are crucial regulators of 46 
intracellular Ca
2+
 signaling. In this way, Bcl-2 proteins affect various targets related to 47 
intracellular Ca
2+
 homeostasis 
3-5
. More specific, this protein family was found to regulate the 48 
mitochondrial voltage-dependent anion channels 
6-8
, plasma-membrane Ca
2+
-ATPases 
9
, 49 
sarco/endoplasmic-reticulum Ca
2+
-ATPases (SERCA) 
10
, Bax inhibitor 1 
11,12
, inositol 1,4,5-50 
trisphosphate (IP3) receptors (IP3R) 
13-15
 and ryanodine receptors (RyRs) 
16
.  51 
Anti-apoptotic Bcl-2 proteins are characterized by the presence of four Bcl-2 homology (BH) 52 
domains important for their biological function 
17
. Although their structural organization is 53 
very similar, Bcl-2 and Bcl-XL may act in very different ways on their targets. As such, the 54 
BH4 domain of Bcl-2 is critical for binding to a site in the regulatory domain of the IP3R (a.a. 55 
1389-1408 for mouse IP3R1) thereby inhibiting IP3-induced Ca
2+
 release 
14,18
. In contrast, the 56 
BH4 domain of Bcl-XL fails to bind to this IP3R domain and to inhibit IP3Rs 
19
. Moreover, we 57 
showed that this difference between the BH4 domains of Bcl-2 and Bcl-XL can largely be 58 
attributed to a single amino acid change (Lys17 in BH4-Bcl-2 corresponding to Asp11 in 59 
BH4-Bcl-XL) in the center of their respective BH4 domains. Indeed, the mutated BH4
K17D
 60 
domain of Bcl-2 and mutated full-length Bcl-2
K17D 
are greatly impaired in targeting and 61 
regulating the IP3R.  62 
We recently showed that, similar to its interaction with the IP3R, Bcl-2 via its BH4 domain 63 
targets a RyR region (a.a. 2263-2688 for mink RyR3) containing a highly conserved 64 
regulatory site (a.a. 2309-2330 for mink RyR3), which shows striking resemblance to the 65 
known Bcl-2 binding site on the IP3R 
16
. The interaction of Bcl-2 and the RyR via its BH4 66 
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domain results in an inhibition of RyR-mediated Ca
2+
 release. The Bcl-2
K17D
 mutant does not 67 
show a dramatic loss of binding to the RyR and is as potent as wild-type Bcl-2 in inhibiting 68 
RyR-mediated Ca
2+
 release. These results may indicate that in contrast to the IP3R, which is 69 
differentially targeted by Bcl-2 and Bcl-XL, RyRs might have a common interaction site for 70 
both proteins and do not distinguish between these two proteins for their regulation. 71 
In this paper, we show that similarly to Bcl-2, Bcl-XL binds to the RyR via a site located in its 72 
central, modulatory domain, thereby inhibiting RyR-mediated Ca
2+
 release. Although the BH4 73 
domain of Bcl-XL was sufficient for inhibiting RyRs, we found that in full-length Bcl-XL not 74 
only the BH4 domain but also the BH3 domain contributed to Bcl-XL/RyR-complex 75 
formation. In particular, we identified Lys87, located in the BH3 domain of Bcl-XL, as an 76 
important contributor of Bcl-XL binding to the RyR. 77 
78 
5 
 
Results 79 
Bcl-XL binds to RyR3 80 
Bcl-2
K17D
 is a Bcl-2 mutant based on a critical difference between the BH4 domains of Bcl-2 81 
and Bcl-XL and is impaired in binding to and regulating IP3Rs 
19
. However, this mutant still 82 
binds to and regulates RyRs with similar efficiencies as wild-type Bcl-2 
16
, suggesting that 83 
Bcl-XL may also bind to and regulate RyRs. Hence, we performed co-immunoprecipitation 84 
studies using lysates from HEK293 cells stably overexpressing RyR3 (HEK RyR3). In these 85 
cells, transiently overexpressed 3XFLAG-tagged Bcl-XL co-immunoprecipitated with RyR3 86 
indicating the formation of RyR3/Bcl-XL complexes (Fig. 1A and Supplementary Fig. 1A for 87 
uncropped Western-blot images). 88 
In our previous work we reported that the interaction between Bcl-2 and the RyR occurred via 89 
the BH4 domain of Bcl-2 and a central regulatory domain of the RyR (a.a. 2263-2688 for 90 
mink RyR3) 
16
. To examine whether a direct interaction between RyRs and the BH4 domain 91 
of Bcl-XL exists and whether this interaction occurs via the same or similar domains, surface 92 
plasmon resonance (SPR) experiments were performed (Fig. 1B). A concentration-dependent 93 
binding between biotin-BH4-Bcl-XL immobilized to streptavidin coated SPR chips, and the 94 
purified GST-RyR3 domain (mink RyR3, a.a. 2263-2688) could be detected. In contrast, but 95 
consistent with our previous observations, purified GST-tagged IP3R1 domain 3 (mouse 96 
IP3R1, a.a. 923-1581), which is known to bind to the BH4 domain of Bcl-2, failed to bind to 97 
biotin-BH4-Bcl-XL 
19
. While biotin-BH4-Bcl-XL was able to bind to the GST-RyR3 domain, 98 
it seemed to be less effective than biotin-BH4-Bcl-2 
16
. To confirm the proper loading of the 99 
biotin-BH4-Bcl-XL peptide to the sensor chip, we monitored the binding of an antibody 100 
directed against the BH4 domain of Bcl-XL, which caused a prominent increase in resonance 101 
unit (RU) values (Supplementary Fig. 2). Collectively, these results indicate that the 102 
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interaction of Bcl-XL with the RyR3 is direct and that Bcl-XL via its BH4 domain targets the 103 
same domain as Bcl-2 on the RyR. However, the BH4 domain of Bcl-XL seems to have a 104 
lower affinity for the GST-RyR3 domain compared to the BH4 domain of Bcl-2. This could 105 
indicate that biotinylation of the BH4 domain of Bcl-XL influences its binding capabilities 106 
more than is the case for the BH4 domain of Bcl-2. Alternatively, other domains besides Bcl-107 
XL’s BH4 domain may be involved in the interaction of full-length Bcl-XL with the RyR. 108 
Therefore, we wanted to identify if other domains besides the BH4 domain of Bcl-XL are 109 
important for interacting with the RyR. 110 
Superposition of the 3D-structures of Bcl-2 and Bcl-XL reveals a spatial resemblance of Lys17 111 
in the BH4 domain of Bcl-2 with Lys87 in the BH3 domain of Bcl-XL 112 
To identify the contribution and involvement of other Bcl-XL domains for targeting RyR 113 
channels, an in silico superposition of the Bcl-2 (PDB-entry 4AQ3 
20
) and Bcl-XL (PDB-entry 114 
1R2D 
21
) structures was performed with the aid of PyMOL (The PyMOL Molecular Graphics 115 
System, Version 1.5.0.4 Schrödinger, LLC.). This superposition allowed the comparison of 116 
corresponding residues in the 3D-structures of Bcl-2 and Bcl-XL (Fig. 2). This analysis 117 
revealed that the positively charged ε-amino terminus of the side chain of Lys87 in Bcl-XL, 118 
located in the BH3 domain, is in the same spatial constraints as the positively charged ε-119 
amino terminus of the side chain of Lys17 located in the BH4 domain of Bcl-2. Furthermore, 120 
Lys87 did not seem to be part of the hydrophobic cleft of Bcl-XL, as it was directed towards 121 
the space facing the BH4 domain.  122 
 123 
The Bcl-XL
K87D
 mutant is impaired in RyR3 binding  124 
The relevance of Lys87 in Bcl-XL for RyR binding was addressed via mammalian protein-125 
protein interaction trap (MAPPIT) 
22
, an in cellulo protein-protein interaction assay. MAPPIT 126 
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is based on the functional complementation of cytokine receptor signaling. To study the 127 
possible existence of RyR/Bcl-XL complexes, the RyR3 domain was cloned downstream of a 128 
chimeric cytokine receptor (RyR3 bait), consisting of the extracellular domain of the 129 
erythropoietin (Epo) receptor fused to the transmembrane and cytosolic part of the leptin 130 
receptor. In the latter, three tyrosines were mutated to phenylalanine to down regulate receptor 131 
signaling. Bcl-XL or the Bcl-XL
K87D
 mutant were cloned downstream of a part of the 132 
glycoprotein 130 receptor (Bcl-XL or Bcl-XL
K87D
 prey). If the Bcl-XL and Bcl-XL
K87D
 prey 133 
constructs interact with the RyR3 bait construct, functional complementation of the chimeric 134 
cytokine receptor occurs, leading to ligand-dependent downstream STAT signaling. The latter 135 
is monitored via a luciferase reporter assay driven by a STAT-sensitive promoter. We also 136 
used the SV40 large antigen T (irrelevant prey) as a prey to monitor the signal representing 137 
the non-specific binding to RyR3. As a negative control, binding of the chimeric cytokine 138 
receptor without the RyR3 fragment (no bait) to the two Bcl-XL preys was also assessed. 139 
These MAPPIT results confirmed the data obtained via SPR and co-immunoprecipitation 140 
experiments, showing that Bcl-XL could interact with the RyR3 domain in a cellular context 141 
(Fig. 3A, top). Moreover, the Bcl-XL
K87D
 mutant was severely impaired in interacting with the 142 
RyR3 domain without affecting its expression (Fig. 3A, bottom panel and Supplementary Fig. 143 
1B for uncropped Western-blot images). No binding was detected when the RyR3 domain 144 
was not present in the bait vector (Fig. 3A, top panel), indicating that the interaction was 145 
specific.  146 
The impact of mutating Lys87 into Asp was also examined in the context of the full-length 147 
RyR3 protein using co-immunoprecipitation experiments. Consistent with the MAPPIT data, 148 
3XFLAG-tagged Bcl-XL
K87D
 displayed a reduced affinity for full-length RyR3 channels (Fig. 149 
3B and Supplementary Fig. 1C for uncropped Western-blot images).  150 
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Taken together, these data indicate that Bcl-XL, similarly to Bcl-2, binds via its BH4 domain 151 
to the same regulatory domain on RyR3. However, whereas for Bcl-2 the BH4 domain 152 
appears to be the main determinant for complex formation with RyR channels, it seems that 153 
for Bcl-XL both the BH4 domain and the BH3 domain, likely via Lys87, contribute to the 154 
interaction with RyR channels.  155 
 156 
Bcl-XL, but not Bcl-XL
K87D
, inhibits RyR3-mediated Ca
2+
 release 157 
Driven by the fact that Bcl-XL can bind to RyR3, we examined whether Bcl-XL could 158 
modulate RyR-mediated Ca
2+
 release (Fig. 4). Single-cell cytosolic [Ca
2+
] measurements in 159 
HEK RyR3 cells loaded with Fura-2-AM were performed (Fig. 4A). An empty vector 160 
(pCMV24) control, 3XFLAG-tagged Bcl-XL or the 3XFLAG-tagged Bcl-XL
K87D
 mutant were 161 
transiently transfected into the HEK RyR3 cells. An mCherry coding plasmid was co-162 
transfected (at a 1:3 ratio) to identify transfected cells. After chelating extracellular Ca
2+
 with 163 
BAPTA (3 mM), caffeine (1.5 mM) was applied to induce RyR-mediated Ca
2+
 release. 164 
Overexpression of 3XFLAG-tagged Bcl-XL inhibited caffeine-induced Ca
2+
 release compared 165 
to the empty vector control. The Bcl-XL
K87D
 mutant failed to inhibit caffeine-induced Ca
2+
 166 
release (Fig. 4B), correlating with its poor RyR3-binding properties. To exclude that the 167 
observed reduction in caffeine-induced Ca
2+
 release upon Bcl-XL overexpression would have 168 
been due to an indirect effect via lowering of the Ca
2+
-filling state of the endoplasmic 169 
reticulum (ER), we determined the amount of thapsigargin (1 µM)-releasable Ca
2+
. This 170 
irreversible SERCA inhibitor causes a depletion of the ER Ca
2+
 stores and provides a good 171 
measure for the ER Ca
2+
-store content. The ER Ca
2+
-store content was not affected by 172 
overexpression of 3XFLAG-tagged Bcl-XL (Fig. 4C). This supports the view that Bcl-XL, 173 
similarly to Bcl-2, suppresses RyR-mediated Ca
2+
 release.  174 
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 175 
The BH4 domain of Bcl-XL by itself seems sufficient to inhibit RyR-mediated Ca
2+
 release 176 
In order to assess whether the BH4 domain of Bcl-XL is sufficient for inhibiting RyR-177 
mediated Ca
2+
 release, Fluo-3-AM loaded HEK RyR3 cells were loaded acutely with the BH4 178 
domain of Bcl-XL, a control peptide or the vehicle via electroporation (Fig. 5A). The BH4 179 
domain of Bcl-XL, but not a control peptide, suppressed caffeine (1 mM)-induced Ca
2+
 180 
release. The BH4 domain of Bcl-XL inhibited caffeine-induced Ca
2+
 release in a 181 
concentration-dependent manner (Fig. 5B). This indicates that the BH4 domain of Bcl-XL was 182 
sufficient for inhibiting RyR-mediated Ca
2+
 release. 183 
We also assessed whether the BH4 domain of Bcl-XL could inhibit endogenous RyR channels 184 
by using 14- to 18-day-old rat hippocampal cultures known to express different RyR isoforms 185 
23
. The experimental set-up was identical to the one previously used for characterization of the 186 
effect of the BH4 domain of Bcl-2 on native RyRs 
16
. Cytosolic [Ca
2+
] was monitored in 187 
GCaMP3-expressing hippocampal neurons. The BH4 domain of Bcl-XL, a control peptide or 188 
the vehicle were introduced into the neurons via a patch pipette. After loading the neuron for 189 
five minutes with the peptides or vehicle, cytosolic [Ca
2+
] measurements were started. RyR-190 
mediated Ca
2+
 release was triggered via a local puff of caffeine (10 mM) delivered via a 191 
second patch pipette positioned next to the neuron. A time lapse (Fig. 5C) and a [Ca
2+
] trace 192 
(Fig. 5D) of a typical experiment are shown for each condition. Loading of the neurons with 193 
the BH4 domain of Bcl-XL (20 µM) caused a significant reduction of the caffeine-induced 194 
Ca
2+
 release compared to the control peptide (Fig. 5 D, E). These results indicate that the BH4 195 
domain of Bcl-XL can regulate endogenously expressed RyR channels. 196 
 197 
Bcl-XL and its BH4 domain directly inhibit RyRs at the level of the ER 198 
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Bcl-XL and its isolated BH4 domain as a synthetic peptide inhibit the caffeine-induced [Ca
2+
] 199 
rise in the cytosol. Bcl-XL has also been implicated in the control of mitochondrial Ca
2+
 200 
transport at the level of VDAC1. Bcl-XL was shown to inhibit Ca
2+
 uptake into the 201 
mitochondria 
6,24
. However, it was also reported that Bcl-XL could stimulate mitochondrial 202 
Ca
2+
 uptake 
25
. The latter effect could result in a decrease in caffeine-induced [Ca
2+
] rise in 203 
the cytosol. Therefore, we set out to document whether the decrease in caffeine-induced Ca
2+
 204 
release in the cytosol by Bcl-XL is due to a decreased Ca
2+
 release from the ER or to an 205 
increased Ca
2+
 accumulation into the mitochondria. Direct ER-Ca
2+
 measurements were 206 
performed in HEK RyR3 cells utilizing a recently described green fluorescent CEPIA1 207 
protein, that is targeted to the lumen of the ER (G-CEPIA1er) 
26
. HEK RyR3 cells were 208 
transiently transfected with the empty vector (pCMV24) as control or with 3XFLAG-tagged 209 
Bcl-XL in combination with the G-CEPIA1er-encoding vector (at a 3:1 ratio). G-CEPIA1er-210 
positive cells were selected and measurements were performed as in Fig. 4A. A typical 211 
average trace of one experiment and the quantification of all performed experiments are 212 
shown in Fig. 6A and B, respectively. These results indicate that overexpression of 3XFLAG-213 
Bcl-XL suppressed the caffeine-induced Ca
2+
 release from the ER, supporting a model in 214 
which the inhibitory effect of Bcl-XL on RyR-mediated [Ca
2+
] rise in the cytosol occurs at 215 
least in part due to inhibition of the Ca
2+
 release from the ER. Finally, we set out to directly 216 
measure the effect of the BH4 domain of Bcl-XL on caffeine-induced mitochondrial Ca
2+
 217 
entry. Rhod-FF-loaded HEK RyR3 cells were electroporated with either the vehicle (DMSO) 218 
or the BH4 domain of Bcl-XL (10 and 20 µM) and then stimulated with caffeine. Caffeine 219 
stimulation resulted in an increase in mitochondrial [Ca
2+
] (Fig. 6C). Compared to the vehicle 220 
control however, the BH4 domain of Bcl-XL potently inhibited the mitochondrial Ca
2+
 entry 221 
(Fig. 6 C, D). Furthermore, the effectiveness of BH4-Bcl-XL to inhibit caffeine-induced 222 
[Ca
2+
] rise in the mitochondria seemed higher than for inhibiting the caffeine-induced [Ca
2+
] 223 
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rise in the cytosol, because 10 M BH4-Bcl-XL inhibited caffeine-induced Ca
2+
 release in the 224 
cytosol by about 50% but inhibited caffeine-induced Ca
2+
 uptake in the mitochondria by about 225 
90%. Taken together these data suggest that BH4-Bcl-XL likely inhibits, rather than 226 
stimulates, mitochondrial Ca
2+
 accumulation. This is consistent with our recent findings 227 
showing that BH4-Bcl-XL directly interacts with VDAC1 and suppressed VDAC1-mediated 228 
Ca
2+
 transfer into the mitochondria 
27
. These experiments indicate that Bcl-XL can directly 229 
inhibit the caffeine-induced Ca
2+
 release at the level of the ER and potently inhibit 230 
mitochondrial Ca
2+
 uptake under these experimental settings. We therefore conclude that the 231 
observed decrease in caffeine-induced Ca
2+
 release in the cytosol (Fig. 4 and 5) is mainly due 232 
to a direct inhibition of RyR3.233 
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Discussion 234 
The main conclusion of this paper is that Bcl-XL binds to and regulates RyR3 channels. 235 
Similarly to Bcl-2, Bcl-XL targets the central modulatory domain of the RyR protein, thereby 236 
suppressing RyR-mediated Ca
2+
 release. Moreover, the BH4 domain of Bcl-XL was sufficient 237 
to inhibit both over- and endogenously expressed RyR channels in HEK293 cells or primary 238 
rat hippocampal neurons respectively. Consistent with this, the BH4 domain of Bcl-XL could 239 
bind to the purified RyR3 domain. However, the RyR3-binding efficiency of the BH4 domain 240 
of Bcl-XL seemed much lower than that of the BH4 domain of Bcl-2. Via an in silico 241 
superposition of the Bcl-2 and Bcl-XL crystal structures, a spatial overlap was observed 242 
between Lys17 in the BH4 domain of Bcl-2 and Lys87 in the BH3 domain of Bcl-XL: the 243 
positively charged ε-amino groups of their side chains coincide in space. Consistent with the 244 
moderate RyR3-binding properties of the isolated BH4 domain of Bcl-XL, we found that 245 
Lys87 from Bcl-XL played a prominent role in binding to and regulating RyR3.  246 
The association of Bcl-XL with RyR channels and its functional implications appear to be 247 
very similar as the ones observed for Bcl-2, since i) RyR3/Bcl-XL binding is direct; ii) the 248 
binding of Bcl-XL to RyR3 occurs, at least in part, via the BH4 domain; iii) Bcl-XL 249 
overexpression inhibits RyR-mediated Ca
2+
 release; and iv) the BH4 domain of Bcl-XL is also 250 
sufficient to suppress RyR activity. These findings correlate with the fact that the Bcl-2
K17D
 251 
mutant and BH4-Bcl-2
K17D
 remain capable of binding to and regulating RyR channels, 252 
although this mutation changes the lysine critical for binding to the IP3R into the Asp11 253 
residue in the BH4 domain of Bcl-XL 
16
. This lack of selectivity between Bcl-2 and Bcl-XL 254 
may illustrate an important difference between IP3R- and RyR-mediated Ca
2+ 
release. 255 
However, the binding of Bcl-XL versus Bcl-2 to RyRs in native tissues expressing RyRs 256 
ought to be further explored. In particular, it will be important to carefully analyze the Bcl-2- 257 
and Bcl-XL-expression levels in the relevant tissues and to determine whether a preferential 258 
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binding of Bcl-2 or Bcl-XL to RyR channels exists in cells expressing both Bcl-2 and Bcl-XL. 259 
Despite these similarities, the molecular determinants underlying RyR/Bcl-XL-complex 260 
formation do not seem identical to those of Bcl-2, because the BH4 domain of Bcl-XL by 261 
itself displays rather moderate RyR3-binding properties. As a consequence, additional 262 
domains seem to be involved in RyR/Bcl-XL-complex formation. Here, we identified Lys87, 263 
located in the BH3 domain of Bcl-XL, as a critical determinant contributing to binding to and 264 
regulating RyR channels. Despite the importance of Lys87, the BH4 domain of Bcl-XL alone 265 
was able to suppress RyR activity. 266 
The BH4 domain of Bcl-XL has been implicated in numerous studies to display strong anti-267 
apoptotic and protective effects against a wide variety of insults and triggers, including in the 268 
heart 
28-30
, endothelial cells 
31,32
, blood cells 
33-35
, pancreatic islets 
36
 and neurons 
37
. Many of 269 
the cell types and tissues reported to benefit from the BH4 domain of Bcl-XL for their survival 270 
endogenously express RyR channels (cardiomyocytes, lymphocytes, pancreatic islets and 271 
neurons). Furthermore, in many apoptotic paradigms, reactive oxygen species (ROS) are 272 
implicated. ROS can impact the redox state and activity of the RyR channels (reviewed by 
38
). 273 
Mild increases in ROS moderately increase RyR activity by increasing its sensitivity for Ca
2+ 274 
39
. However, severe ROS production associated with oxidative stress (e.g. in the context of 275 
ischemia/reperfusion injury) can lead to a continuously opening of the RyR channels, 276 
provoking an excessive Ca
2+
 leak from the ER or sarcoplasmic reticulum 
40
. In the context of 277 
the heart, ROS has been clearly implicated to cause unzipping of the interdomain interactions 278 
critical for RyR2-channel stabilization 
41,42
. During oxidative stress conditions, the BH4 279 
domain of Bcl-XL may thus inhibit excessive RyR-mediated Ca
2+
 release from the 280 
intracellular Ca
2+
 stores in addition to exerting its protective effects at the mitochondria, 281 
thereby providing additional protection against cell death.  282 
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RyRs have important physiological functions in a variety of excitable cells and tissues, 283 
including skeletal muscle, cardiac muscle, neurons and pancreatic cells 
43-46
.  Furthermore, 284 
dysregulation of RyRs, either by somatic mutations or by altered expression levels, has been 285 
implicated in a variety of pathophysiological conditions, including malignant hyperthermia 286 
and central core disease 
47,48
, cardiac diseases 
49-51
 and neurodegenerative diseases like 287 
Alzheimer’s disease 52-54 and Huntington’s disease 55. At this point, the existence and 288 
physiological relevance of RyR/Bcl-2- and RyR/Bcl-XL-complex formation in these tissues 289 
and their potential disturbance in RyR-associated pathophysiologies will require further 290 
research.  291 
In conclusion, our data further expand the number of Bcl-2-family members that are able to 292 
form protein complexes with RyR channels, thereby underpinning their critical role in 293 
regulating intracellular Ca
2+
 dynamics at the level of intracellular Ca
2+
-release channels. 294 
295 
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Materials and methods 296 
Chemicals, antibodies and peptides 297 
Unless otherwise specified, all chemicals were purchased from Sigma-Aldrich (St. Louis, 298 
MO, USA). The following antibodies were used: mouse monoclonal anti-actin antibody, anti-299 
FLAG M2 antibody and HRP-conjugated anti-FLAG M2 antibody (Sigma-Aldrich), mouse 300 
monoclonal anti-RyR antibody 34C (Thermo Scientific, Rockford, IL, USA, or 301 
Developmental Studies Hybridoma Bank, University of Iowa, Iowa, USA) and mouse 302 
monoclonal anti-Bcl-XL antibody YTH-2H12 (Trevigen, Gaithersburg, WV, USA). The 303 
sequences of the peptides used in this study were:  304 
Biotin-BH4-Bcl-XL:   Biotin-MSQSNRELVVDFLSYKLSQKGYSW    305 
(also used without the biotin tag) 306 
Biotin-scrambled BH4-Bcl-XL: Biotin-WYSKQRSLSGLVMYVLEDKNSQFS 307 
Control peptide:   WYEKQRSLHGIMYYVIEDRNTKGYR 308 
These peptides were synthesized by Life Tein (Hillsborough, NJ, USA) with a purity of at 309 
least 85%. 310 
Plasmids, constructs and protein purifications 311 
3XFLAG-Bcl-XL was obtained as previously described 
19
. The 3XFLAG-Bcl-XL
K87D
 mutant 312 
was obtained by PCR site-directed mutagenesis utilizing the following primers: forward: 313 
5’ATCCCCATGGCAGCAGTAGATCAAGCGCTGAGGGAGGCA3’, and reverse: 314 
5’TGCCTCCCTCAGCGCTTGATCTACTGCTGCCATGGGGAT3’.  The pCMV G-315 
CEPIA1er containing plasmid was a gift from Dr. Masamitsu Iino (Addgene plasmid # 316 
16 
 
58215) 
26
. The GST-IP3R1 domain 3 construct and the GST-RyR3 construct were obtained 317 
and purified as described 
16
. 318 
Cell culture, transfections and dissociated hippocampal cultures 319 
All media and supplements added to the medium used in this paper were purchased from Life 320 
Technologies (Ghent, Belgium). HEK293 cells stably overexpressing RyR3 were cultured at 321 
37°C in a 5% CO2 incubator in α-Minimum Essential Medium supplemented with 10% fetal 322 
calf serum, 100 IU/mL penicillin, 100 μg/mL streptomycin, 2 mM glutamax and 800 µg/mL 323 
G418 
56
. HEK293 cells were grown in Dulbecco’s Modified Eagle Medium containing 4500 324 
mg/L glucose, 10% fetal bovine serum and 50 µg/mL gentamicin 
57
.  325 
24 hours after seeding, the 3XFLAG-Bcl-XL or the 3XFLAG-Bcl-XL
K87D
 mutant construct 326 
were introduced into the HEK RyR3 cells utilizing JETPrime transfection reagent (Polyplus 327 
Transfections, Illkirch, France) according to the manufacturer’s protocol. 48 hours later the 328 
cells were harvested and lysed utilizing a CHAPS-based lysis buffer (pH 7.5, 50 mM Tris-329 
HCl, 100 mM NaCl, 2 mM EDTA, 50 mM NaF, 1 mM Na3VO4, 1% CHAPS and protease 330 
inhibitor tablets (Roche, Basel, Switzerland)). For single-cell cytosolic [Ca
2+
] measurements 331 
the same constructs or the empty pCMV24 vector were introduced 48 hours after seeding in 332 
the HEK RyR3 cells utilizing X-tremeGENE HP DNA transfection reagent (Roche) according 333 
to the manufacturer’s protocol. A pcDNA 3.1(-) mCherry expressing vector was co-334 
transfected at a 1:3 ratio as a selection marker. For direct ER [Ca
2+
] measurements, the G-335 
CEPIA1er construct was co-transfected (ratio 3:1) and used as selection marker instead of the 336 
mCherry expressing vector. Dissociated hippocampal cultures were obtained as described 337 
previously 
58
. All animal experiments were performed according to approved guidelines. 338 
 339 
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SPR analysis 340 
SPR analysis was performed using a Biacore T200 (GE Healthcare, Diegem, Belgium). 341 
Immobilization to the streptavidin-coated sensor chip (BR-1005-31; GE Healthcare) and SPR 342 
measurements were performed as described previously 
19
. NaOH (50 mM) with 0.0026% SDS 343 
was used as a regeneration buffer. 344 
Immunoblot analysis 345 
Samples were prepared and used as previously described 
19
. For visualization of RyRs, 346 
NuPAGE 3-8% tris-acetate gels were run. Detection was performed using Pierce ECL 347 
Western Blotting Substrate (Thermo Scientific) when using the Chemidoc™ MP system (Bio-348 
Rad, Nazareth Eke, Belgium) or an X-OMAT 1000 processor (Kodak, Zaventem, Belgium). 349 
When using the Odyssey imager (Westburg, Leusden, The Netherlands) detection was 350 
performed using anti-mouse-IRDye800 (green) or anti-rabbit-IRDye700 (red) as secondary 351 
antibodies (Thermo Scientific). 352 
Co-immunoprecipitation experiments 353 
Co-immunoprecipitation experiments were performed utilizing a co-immunoprecipitation kit 354 
(Thermo Scientific). RyR antibody or mouse IgG control antibody (Santa Cruz 355 
Biotechnology, Heidelberg, Germany) was immobilized according to the manufacturer’s 356 
protocol. Gelatine was removed from the IgG control antibody utilizing a Pierce Antibody 357 
Clean-up Kit (Thermo scientific). Precleared HEK RyR3 lysates containing the 3XFLAG-358 
Bcl-XL constructs (150 µg) were added to the resin to which the antibodies were immobilized 359 
and allowed to incubate overnight at 4°C. The next day, the resin was washed at least five 360 
times utilizing the CHAPS-based lysis buffer. The immune complexes were eluted by boiling 361 
18 
 
(95°C) in 50 µL 2X LDS (Life Technologies) supplemented with 1/200 β-mercaptoethanol 362 
for 5 min. 363 
MAPPIT 364 
The RyR3 domain was amplified by PCR using the following primers, forward: 365 
5’TAGTTGTCGACGAAGAGAGAAGTCATGGAGGA3’, and reverse: 366 
5’TAGTTGCGGCCGCCTATTTGGTCCTCTCCACA3’, and cloned in the pSEL+2L bait 367 
vector 
59
, using the restriction enzymes SalI and NotI. Bcl-XL was cloned in the pMG1-GW 368 
plasmid (prey vector) 
22
 using the Gateway recombination technology as described by the 369 
manufacturer (Life Technologies). Utilizing the same primers as described before, the Bcl-370 
XL
K87D
 mutation was also introduced in this construct via site directed mutagenesis. The 371 
MAPPIT analyses were done as previously described 
22
 with minor changes. Briefly, HEK293 372 
cells were seeded in 96-well plates. Six wells per condition were transfected with the different 373 
combinations of bait, prey and reporter plasmid (rPAP1-luci) using the calcium phosphate 374 
method. The next day, half of the wells were stimulated with 5 ng/mL Epo while the other 375 
half were left untreated. 24 hours later the cells were lysed and after the addition of substrate 376 
the luciferase activity was determined using a luminometer. The fold induction was obtained 377 
by dividing the average value of the stimulated cells by the average value of the non-378 
stimulated cells.  379 
Electroporation loading  380 
Electroporation loading of HEK RyR3 cells was performed as previously described 
16,60
. 381 
Single-cell cytosolic Ca
2+
 imaging 382 
19 
 
Fura-2-AM and Fluo-3-AM [Ca
2+
] measurements in HEK RyR3 cells and GCaMP3 single-383 
cell [Ca
2+
] measurements in dissociated hippocampal neurons were performed as previously 384 
described 
16
.  385 
Single-cell ER Ca
2+
 imaging 386 
The G-CEPIA1er construct was introduced into HEK RyR3 cells as described above. A Zeiss 387 
Axio Observer Z1 Inverted Microscope equipped with a 20x air objective and a high-speed 388 
digital camera (Axiocam Hsm, Zeiss, Jena, Germany) were used for these measurements. 389 
Changes in fluorescence were monitored in the GFP channel (480/520 excitation/emission). 390 
To chelate extracellular Ca
2+
, 3 mM BAPTA (Alfa Aesar, Ward Hill, MA, USA) was added. 391 
One minute later 1.5 mM caffeine was added to trigger RyR-mediated Ca
2+
 release. All traces 392 
were normalized (F/F0) where F0 is the starting fluorescence of each trace. 393 
Single-cell mitochondrial Ca
2+
 imaging 394 
HEK RyR3 cells were loaded for 30 min with 5 µM Rhod-FF-AM. Subsequently, cells were 395 
subjected to de-esterification over 15 min. During this time the BH4 domain peptides were 396 
introduced into the cells using the in situ electroporation technique 
60
. Fluorescence-intensity 397 
changes in mitochondria were analyzed with custom-developed FluoFrames software. For 398 
each individual trace, the relative change of fluorescence (F/F) was calculated. F/F equals 399 
[Ft-F0/F0], with F0 denoting the fluorescence before stimulation with caffeine and Ft the 400 
fluorescence at different time points after caffeine stimulation. Subsequently, relative 401 
mitochondrial [Ca
2+
] changes were quantified as the area under the curve of the various Ca
2+ 402 
traces. 403 
Statistical analysis 404 
20 
 
Two-tailed student’s t-tests were performed when two conditions were compared. When 405 
comparing three conditions a one-way ANOVA with Bonferroni’s multiple comparison test 406 
was performed. * indicates significantly different results (p<0.05). Exact p-values are 407 
indicated in the figure legends, where available. 408 
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Figure 1. Bcl-XL binds to a central regulatory region of RyR3  570 
(A) Co-immunoprecipitation experiments were performed utilizing cell lysates from HEK 571 
RyR3 cells transiently overexpressing 3XFLAG-Bcl-XL. RyR3 was immunoprecipitated from 572 
these lysates utilizing a pan-RyR antibody. An anti-FLAG-HRP conjugated antibody was 573 
used for detecting co-immunoprecipitated 3XFLAG-Bcl-XL. Immunoblot showing the 574 
immunoprecipitated RyR3 (top) and co-immunoprecipitated 3XFLAG-tagged Bcl-XL 575 
(bottom). Immunoprecipitations using non-specific IgG antibodies were applied as negative 576 
controls. All experiments were performed at least three times utilizing each time 577 
independently transfected cells and freshly prepared HEK RyR3 lysates. All samples were run 578 
using the same experimental conditions on the same gel/blot. The uncropped image is shown 579 
in Supplementary Fig. 1A. (B) Sensorgrams of the surface plasmon resonance experiments 580 
expressed in RU as a function of time. The biotin-BH4-Bcl-XL peptide and the scrambled 581 
peptide were immobilized on different channels of a streptavidin-coated sensor chip. The 582 
channels on the chip were exposed to the indicated concentrations of purified GST-fusion 583 
proteins (GST-IP3R1 domain 3 and GST-RyR3 domain). Binding of the GST-tagged proteins 584 
to the scrambled peptides was subtracted from each sensorgram. GST-IP3R1 domain 3 bound 585 
stronger to the scrambled peptide than to the biotin-BH4-Bcl-XL resulting in apparent 586 
negative values after this correction. The black arrow indicates the start of the association 587 
phase (addition of the GST-tagged proteins) and the grey arrow indicates the start of the 588 
dissociation phase (running buffer alone). Each sensorgram depicts the average of three 589 
experiments (full line) ± S.D. (dashed lines).  590 
 591 
 592 
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Figure 2. Spatial resemblance of Lys17 in the BH4 domain of Bcl-2 and Lys87 in the 593 
BH3 domain of Bcl-XL 594 
Image showing the 3D-structures for Bcl-2 (left), Bcl-XL (middle) and their in silico 595 
superposition (right). Lys17 in the BH4 domain of Bcl-2 and Lys87 in the BH3 domain of 596 
Bcl-XL are indicated with arrows. The a.a. in green represent Lys17 and His94 in the BH4 and 597 
BH3 domain of Bcl-2 respectively. The a.a. in orange represent Asp14 and Lys87 in the BH4 598 
and BH3 domains of Bcl-XL respectively. The images were obtained by using PyMOL.  599 
 600 
Figure 3. The Bcl-XL
K87D
 mutant is impaired in RyR3 binding 601 
(A) Top: Representative example of a MAPPIT experiment. The binding is shown as fold 602 
induction value, calculated by dividing the average luciferase value of erythropoietin-603 
stimulated cells by the average of non-stimulated cells. Binding of Bcl-XL (Bcl-XL prey), the 604 
Bcl-XL
K87D
 mutant (Bcl-XL
K87D
 prey) or irrelevant prey control (SV40 large T antigen) to the 605 
RyR3 domain (RyR3 bait) and as negative control the bait vector without RyR3 (No bait) are 606 
shown. Fold induction values at least 4 times higher than the irrelevant prey control are 607 
considered as bona fide protein-protein interactions. Values represent the average of three 608 
repeats within the same experiment ± S.D. All experiments were independently performed at 609 
least three times. Bottom: Odyssey Western blot analyses staining for the FLAG tag of the 610 
prey vector containing Bcl-XL or the Bcl-XL
K87D
 mutant fusion proteins (green) or for actin 611 
(red) as a loading control. All samples were run using the same experimental conditions on 612 
the same gel/blot. The uncropped image is shown in Supplementary Fig. 1B. (B) Co-613 
immunoprecipitations were performed in HEK RyR3 cells transiently overexpressing 614 
3XFLAG-Bcl-XL or 3XFLAG-Bcl-XL
K87D
 similarly as in Fig. 1A. Non-specific IgG 615 
antibodies were applied as negative controls. These experiments were performed at least three 616 
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times utilizing each time independently transfected and freshly prepared HEK RyR3 cell 617 
lysates. All samples were run using the same experimental conditions and were derived from 618 
the same gel/blot, i.e. 3-8 % tris-acetate gels for RyRs and 4-12 % bis-tris gels for 3xFLAG-619 
Bcl-XL. The double lines indicate that an additional empty lane separating the 620 
immunoprecipitated samples and the input samples was removed for the 3XFLAG-Bcl-XL 621 
blot. The uncropped image is shown in Supplementary Fig. 1C. 622 
 623 
Figure 4. Bcl-XL but not Bcl-XL
K87D
 inhibits RyR-mediated Ca
2+
 release 624 
Single-cell cytosolic [Ca
2+
] measurements were performed in HEK RyR3 cells utilizing Fura-625 
2-AM. (A) Average calibrated [Ca
2+
] trace of 15 to 20 HEK RyR3 cells transfected (mCherry 626 
positive) with an empty vector as control (pCMV24), 3XFLAG-Bcl-XL or 3XFLAG-Bcl-627 
XL
K87D
. Addition of BAPTA and caffeine is indicated by the arrows. (B) Quantitative analysis 628 
of the single-cell cytosolic [Ca
2+
] measurements. Values indicate averages of all peak values ± 629 
S.E.M. These experiments were independently performed at least four times (>120 630 
cells/condition) (p=0.008). (C) Quantitative analysis of the ER Ca
2+
-store content. ER-store 631 
content was determined by performing similar experiments as in A except that 1 µM 632 
thapsigargin was used as the stimulus. The values indicate the average area under the curve 633 
(AUC) ± S.E.M. of at least three independent experiments (>80 cells/condition).  634 
 635 
Figure 5. The BH4 domain of Bcl-XL by itself was sufficient to inhibit RyR-mediated 636 
Ca
2+
 release 637 
(A) Representative trace of the performed Fluo-3-AM single-cell cytosolic [Ca
2+
]
 638 
measurements in HEK RyR3 cells loaded by electroporation with either the vehicle (DMSO), 639 
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a control peptide or the BH4 domain of Bcl-XL. The addition of caffeine is indicated by the 640 
arrow. Traces were normalized to the baseline fluorescence ((F-F0)/F0). (B) Quantitative 641 
analysis of the single-cell cytosolic [Ca
2+
] measurements with indicated concentrations of the 642 
BH4 domain of Bcl-XL. Values indicate caffeine-induced Ca
2+ 
release after electroporation 643 
loading with different concentrations of the BH4 domain of Bcl-XL relative to the response 644 
after electroporation loading with the same concentration of the control peptide. Values depict 645 
average ± S.E.M. of at least four independent experiments (p-values were 0.0037, 0.001 and 646 
0.0039 for 10 µM, 20 µM and 40 µM of the BH4 domain of Bcl-XL respectively). (C-E) 647 
Single-cell [Ca
2+
] measurements performed in 14- to 18-day-old hippocampal cultures. 648 
GCaMP3, introduced into these neurons via adeno-associated infection, was used as cytosolic 649 
Ca
2+
 indicator. Utilizing whole-cell voltage clamp the membrane potential of the neurons was 650 
clamped at -60 mV. 20 µM of the BH4 domain of Bcl-XL, a control peptide or the vehicle 651 
(DMSO) was introduced into each measured neuron via the patch pipette. All experiments 652 
were performed in the presence of 1 µM tetrodotoxin. A 10 mM caffeine puff was locally 653 
administered via a second patch pipette positioned 15-25 µm from the soma of the neuron. (C) 654 
Time lapse of a typical experiment for each of the tested conditions. Caffeine was 655 
administered after 60 sec. The scale bar depicts 5 µm. (D) Typical responses to caffeine after 656 
loading the neurons with 20 µM of either the control peptide the BH4 domain of Bcl-XL or 657 
the vehicle. Traces were normalized to the baseline fluorescence ((F-F0)/F0). The arrow 658 
indicates when caffeine was administered. (E) Scatter plot showing peak responses of all 659 
performed measurements and the median (horizontal line). All values were normalized to the 660 
caffeine response after vehicle control treatment (p=0.0037, N=12 and N=15 for the control 661 
peptide and BH4-Bcl-XL respectively). 662 
 663 
 664 
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Figure 6. Bcl-XL and its BH4 domain directly inhibit RyR-mediated Ca
2+ 
release from 665 
the ER 666 
 (A) Typical average normalized (F/F0) traces of single-cell ER [Ca
2+
] measurement 667 
performed in HEK RyR3 cells transfected with G-CEPIA1er plasmid. G-CEPIA1er-positive 668 
cells transfected with the empty control vector (pCMV24) or 3XFLAG-Bcl-XL were selected 669 
for these measurements. After chelating extracellular Ca
2+
 with BAPTA, caffeine was added 670 
to stimulate RyR-mediated Ca
2+
 release (arrows). (B) Quantitative analysis of the performed 671 
experiments. For each trace the caffeine-induced Ca
2+
 release was determined by subtracting 672 
the fluorescence after caffeine addition (during plateau phase) from the fluorescence just 673 
before caffeine addition after normalization. Values depict average ± S.E.M. These 674 
experiments were independently repeated at least four times (>100 cells/condition) 675 
(p=0.0018). (C) Normalized ((F-F0)/F0) representative traces of mitochondrial [Ca
2+
] 676 
measurements. The vehicle (DMSO) or the BH4 domain of Bcl-XL (10 µM and 20 µM) were 677 
introduced into Rhod-FF-loaded HEK RyR3 cells via electroporation loading. Mitochondrial 678 
Ca
2+
 was measured after caffeine (arrow) stimulation. (D) Quantification of the performed 679 
experiments. Values show the average caffeine-induced mitochondrial Ca
2+
 entry as area 680 
under the curve (AUC) ± S.E.M. Experiments were independently performed at least three 681 
times (p<0.0001). 682 
 683 
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Supplementary Figure 1: 
Uncropped western blots used in 
figure 1 (A) and figure 3 (B, C). 
The boxes indicate where the 
figure was cropped in the main 
text. In panel B an additional lane 
was shown in which a TRIP13 
prey was transfected. This protein 
migrates at a different molecular 
weight than the Bcl-XL  preys, con-
firming that the anti-FLAG positive 
signal at 50 kDa are the the Bcl-
XL preys. This lane was excluded 
from the main figure as it was not 
discussed in the main text.
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Supplementary Figure 2: SPR sensorgram showing binding of a BH4-Bcl-XL recognizing antibody 
to the immobilized biotin-BH4-Bcl-XL. The trace was corrected for background binding by 
subtracting binding to the scrambled biotin-BH4-Bcl-XL. The black arrow indicates the start of the 
association phase; the grey arrow indicates the start of the dissociation phase.
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